Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.36 - $2.29 $9,843 - $16,575
7,238 New
7,238 $13,000
Q4 2023

Feb 14, 2024

BUY
$1.08 - $1.92 $131 - $234
122 New
122 $0
Q3 2022

Nov 14, 2022

BUY
$0.71 - $1.17 $193 - $318
272 New
272 $0
Q3 2021

Nov 15, 2021

SELL
$1.89 - $8.53 $5,670 - $25,589
-3,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$2.46 - $3.14 $7,380 - $9,420
3,000 New
3,000 $8,000

Others Institutions Holding CRVS

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $223M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.